Heterocyclic Building Blocks-quinoxaline

Wozniak, Marian; Grzegozek, Maria; Nowak, Krystyna published the artcile< Oxidative amination of some nitroquinoxalines with liquid methylamine/potassium permanganate>, Recommanded Product: 2-Chloro-6-nitroquinoxaline, the main research area is oxidative amination nitroquinoxaline.

5- And 6-nitroquinoxaline and some of their Me and chloro derivatives are aminated in a liquid methylamine solution of potassium permanganate to the corresponding mono- or mono- and bis(methylamino)-substituted compounds The intermediate 5-(methylamino) o-adduct of 6-nitroquinoxaline is detected by 1H NMR. Quantum chem. calculations are used to explain the regioselectivity of the reactions.

Indian Journal of Heterocyclic Chemistry published new progress about Oxidative amination. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, Recommanded Product: 2-Chloro-6-nitroquinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Zhang, Lixi; He, Jingwen; Zhang, Pengfei; Zheng, Kai; Shen, Chao published the artcile< Visible-light-induced decarboxylative alkylation of quinoxalin-2(1H)-ones with phenyliodine(III) dicarboxylates by cerium photocatalysis>, Application In Synthesis of 89898-96-4, the main research area is alkyl quinoxalinone preparation; quinoxalinone phenyliodine dicarboxylate visible light induced alkylation cerium photocatalyst.

3-Alkylquinoxalin-2(1H)-ones I [R1 = H, 6-Me, 7-Cl, etc.; R2 = Me, Et, Pr, propargyl, allyl, Bn; R3 = Me, Et, cyclopropyl, etc.] were prepered via visible-light-induced decarboxylative alkylation of quinoxalin-2(1H)-ones with phenyliodine(III) dicarboxylate using inexpensive CeCl3 as photocatalyst. Novel protocol had advantages of mild conditions, high yields and good substrate scope. Control experiments indicated that radical mechanism was responsible for the present transformation.

Molecular Catalysis published new progress about Dicarboxylic acids, esters Role: RCT (Reactant), RACT (Reactant or Reagent). 89898-96-4 belongs to class quinoxaline, and the molecular formula is C8H5N3O3, Application In Synthesis of 89898-96-4.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Carrer, Amandine; Brion, Jean-Daniel; Messaoudi, Samir; Alami, Mouad published the artcile< Palladium(II)-Catalyzed Oxidative Arylation of Quinoxalin-2(1H)ones with Arylboronic Acids>, Recommanded Product: 7-Nitro-2(1H)-quinoxalinone, the main research area is palladium catalyst oxidative arylation quinoxalinone arylboronic acid.

A straightforward palladium-catalyzed oxidative C-3 arylation of quinoxalin-2(1H)-ones with arylboronic acids is reported. E.g., in presence of Pd(OAc)2 as catalyst and 1,10-phenanthroline as ligand and O2 as oxidant, arylation of 1-methylquinoxalin-2(1H)-one with 4-MeOC6H4B(OH)2 gave 94% I. This protocol is compatible with a wide range of functional groups and allows construction of various biol. important quinoxalin-2(1H)-one backbones.

Organic Letters published new progress about Arylation (oxidative). 89898-96-4 belongs to class quinoxaline, and the molecular formula is C8H5N3O3, Recommanded Product: 7-Nitro-2(1H)-quinoxalinone.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Marques-Gallego, Patricia; Gamiz-Gonzalez, M. Amparo; Fortea-Perez, Francisco R.; Lutz, Martin; Spek, Anthony L.; Pevec, Andrej; Kozlevcar, Bojan; Reedijk, Jan published the artcile< Quinoxaline-2-carboxamide as a carrier ligand in two new platinum(II) compounds: Synthesis, crystal structure, cytotoxic activity and DNA interaction>, Computed Properties of 5182-90-1, the main research area is crystal structure platinum quinoxalinecarboxamide chloro solvent complex; platinum quinoxalinecarboxamide chloro solvent preparation DNA binding unwinding cytotoxicity; ethylguanine substitution platinum quinoxalinecarboxamide chloro solvent DNA model; antitumor platinum quinoxalinecarboxamide chloro solvent complex.

The search for platinum compounds structurally different from cisplatin has led to two new platinum(II) compounds containing quinoxaline-2-carboxamide as a carrier ligand, i.e. cis-[Pt(qnxca)(MeCN)Cl2] (1) and the [Pt(qnxca-H)(DMSO)Cl] (2). Both compounds have been synthesized and characterized using different spectroscopic methods. In addition, single-crystal structures have been determined by X-Ray diffraction for both compounds In each case a square planar Pt(II) is present; in (1) the qnxca is monodentate and neutral, whereas in (2) the ligand has lost a hydrogen, to form the anionic chelating ligand abbreviated as qnxca-H. The biol. activity of both compounds has been investigated in a panel of seven human tumor cells, displaying poor cytotoxic activity, compared to cisplatin. The interaction of the new compounds with 1 or 2 equivalent of 9-ethylguanine has been studied using 1H NMR, 195Pt NMR and ESI-MS spectroscopy, finding poor reactivity of 1 towards the model base, forming only the monosubstituted adduct. Surprisingly, compound 2, which is more sterically crowded, interacts more efficiently with the 9-EtG, forming a bifunctional adduct with two 9-EtG with substitution of the DMSO and the chloride ligand. Unwinding studies of pUC19 plasmid DNA by compound 1 show similar unwinding properties to cisplatin.

Dalton Transactions published new progress about Antitumor agents. 5182-90-1 belongs to class quinoxaline, and the molecular formula is C9H7N3O, Computed Properties of 5182-90-1.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Deng, Jing; Feng, Enguang; Ma, Sheng; Zhang, Yan; Liu, Xiaofeng; Li, Honglin; Huang, Huang; Zhu, Jin; Zhu, Weiliang; Shen, Xu; Miao, Liyan; Liu, Hong; Jiang, Hualiang; Li, Jian published the artcile< Design and synthesis of small molecule RhoA inhibitors: a new promising therapy for cardiovascular diseases?>, Category: quinoxaline, the main research area is quinoxaline derivative preparation SAR drug screen RhoA inhibitory; cardiovascular disease.

RhoA is a member of Rho GTPases, a subgroup of the Ras superfamily of small GTP-binding proteins. RhoA, as an important regulator of diverse cellular signaling pathways, plays significant roles in cytoskeletal organization, transcription, and cell-cycle progression. The RhoA/ROCK inhibitors have emerged as a new promising treatment for cardiovascular diseases. However, to date, RhoA inhibitors are macromols., and to our knowledge, small mol.-based inhibitors have not been reported. In this study, a series of first-in-class small mol. RhoA inhibitors have been discovered by using structure-based virtual screening in conjunction with chem. synthesis and bioassay. Virtual screening of ∼200,000 compounds, followed by SPR-based binding affinity assays resulted in three compounds with binding affinities to RhoA at the micromolar level. Compound I was selected for further structure modifications in considering binding activity and synthesis ease. Forty-one new compounds were designed and synthesized accordingly. It was found that eight showed high RhoA inhibition activities with IC50 values of 1.24 to 3.00 μM. A pharmacol. assay indicated that two compounds II and III demonstrated noticeable vasorelaxation effects against PE-induced contraction in thoracic aorta artery rings and served as good leads for developing more potent cardiovascular agents.

Journal of Medicinal Chemistry published new progress about Amination. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, Category: quinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Rao, Koppaka V.; Jackman, Dennis published the artcile< Reaction of sodium borohydride with heteroaromatic nitro compounds>, Related Products of 23088-24-6, the main research area is quinoxaline nitro reduction; quinoline nitro reduction; tetrahydronitroquinoxaline; dihydronitroquinoline.

Quinoxalines (I, R = 5-, 6-NO2, 6-CN, 6-CO2Et, 6-CF3) and 5-, 6-, 7-, 8-nitroquinoline (II) were reduced selectively by NaBH4 in HOAc at 5° to give 1,2,3,4-tetrahydro-derivatives of I and 1,2-dihydro-derivatives of II resp. 5-Nitroisoquinoline was reduced to the 1,2,3,4-tetrahydro derivative in HOAc at 5° but yielded the 1,2-dihydro derivative in aqueous MeOH.

Journal of Heterocyclic Chemistry published new progress about Reduction. 23088-24-6 belongs to class quinoxaline, and the molecular formula is C9H5N3, Related Products of 23088-24-6.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Rangnekar, D. W.; Tagdiwala, P. V. published the artcile< Synthesis of 6-acetamido-2-substituted quinoxaline derivatives and their use as fluorescent whiteners for polyester fibers>, Application In Synthesis of 6272-25-9, the main research area is quinoxaline acetamido dye polyester; acetamidoquinoxaline fluorescent brightener; polyester disperse dye acetamidoquinoxaline.

6-Nitro-2-chloroquinoxaline  [6272-25-9] was condensed with amines, alcs. and phenols to give 6-nitro-2-substituted quinoxalines. The nitro compounds were reduced to the corresponding amino compounds and then acetylated to yield 6-acetamido-2-substituted quinoxalines. 6-Nitro-2-substituted amino quinoxalines and 6-acetamido-2-substituted quinoxalines were evaluated as disperse dyes and fluorescent brighteners, resp., on polyester fibers.

Dyes and Pigments published new progress about Disperse dyeing. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, Application In Synthesis of 6272-25-9.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Shahin, Mai I.; Abou El Ella, Dalal A.; Ismail, Nasser S. M.; Abouzid, Khaled A. M. published the artcile< Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold>, COA of Formula: C8H4ClN3O2, the main research area is arylaminoquinoxalinone arylaminoquinoxaline ureidoarylaminoquinoxaline preparation VEGFR2 inhibitor; structure arylaminoquinoxalinone arylaminoquinoxaline ureidoarylaminoquinoxaline inhibition VEGFR2 kinase; mol docking arylaminoquinoxalinone arylaminoquinoxaline ATP binding site VEGFR2; calculated lipophilicity solubility absorption CYP 2D6 inhibition arylaminoquinoxalinone arylaminoquinoxaline; Docking study; Kinase; Quinoxaline; Type-II; VEGFR-2.

Arylaminoquinoxalinones I [R = HO; R1 = 4-MeOC6H4NH; R2 = R3NHC(:X)NH, 4-R4C6H4SO2NH, 2-HO2CC6H4CONH, MeCONH; R3 = Ph, 3-ClC6H4, 3-MeC6H4, cyclohexyl; R4 = H, Me; X = O, S], arylaminoquinoxalines I [R = H; R1 = 4-R5C6H4NH; R2 = R3NHC(:X)NH, 4-R4C6H4SO2NH, MeCONH; R3 = Ph, 3-MeC6H4, cyclohexyl; R4 = H, Me; R5 = MeO, Cl; X = O, S] and ureidoarylaminoquinoxalines I [R = H; R1 = 4-(3-R6C6H4NHCONH)C6H4NH; R2 = O2N; R6 = H, Cl] were prepared as ATP-competitive VEGFR-2 inhibitors for potential use as antitumor agents. I (R = HO; R1 = 4-MeOC6H4; R2 = PhNHCONH) was the most effective VEGFR-2 inhibitor of the compounds prepared at a concentration of 10 μM. Mol. docking calculations were performed to rationalize the selectivities of quinoxalines for VEGFR-2; calculated physicochem. properties, absorption, and probabilities of CYP 2D6 inhibition were determined for the compounds

Bioorganic Chemistry published new progress about Biological permeation. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, COA of Formula: C8H4ClN3O2.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Minisci, Francesco; Citterio, Attilio; Vismara, Elena; Giordano, Claudio published the artcile< Polar effects in free-radical reactions. New synthetic developments in the functionalization of heteroaromatic bases by nucleophilic radicals>, Related Products of 5182-90-1, the main research area is lepidine alc nucleophilic radical substitution; hydroxylaminium salt titanium substitution catalyst; hydroxyalkyllepidine; substitution catalyst benzoyl peroxide hydrogen; carbamoylation quinoline acridine pyrazine benzothiazole; heteroaromatic base carbamoylation peroxide catalyst; dioxane hydrofuran lepidine radical substitution.

Direct substitution of protonated heteroaromatic bases by nucleophilic carbon-centered radicals involved use of the redox system N+H3OH/Ti(III) in several solvents, use of benzoyl peroxide in alcs., and carbamoylation by HCONH2 and H2O2 in the presence of catalytic Fe(II). Thus lepidine I (R = H) in MeOH gave 98% I (R = CH2OH) in the presence of benzoyl peroxide. These systems gave hitherto unobtainable substitution products and reactions of industrial interest. Polar effects determine reactivity, selectivity and synthetic applications; in particular the role of the strongly nucleophilic intermediate radicals of pyridinyl type in the rearomatization step is emphasized.

Tetrahedron published new progress about Carbamoylation. 5182-90-1 belongs to class quinoxaline, and the molecular formula is C9H7N3O, Related Products of 5182-90-1.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Niculescu, A. B.; Le-Niculescu, H.; Roseberry, K.; Wang, S.; Hart, J.; Kaur, A.; Robertson, H.; Jones, T.; Strasburger, A.; Williams, A.; Kurian, S. M.; Lamb, B.; Shekhar, A.; Lahiri, D. K.; Saykin, A. J. published the artcile< Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugs>, COA of Formula: C22H21N3O2, the main research area is Alzheimer disease blood biomarker memory pharmacogenomics.

We carried out longitudinal within-subject studies in male and female psychiatric patients to discover blood gene expression biomarkers that track short term memory as measured by the retention measure in the Hopkins Verbal Learning Test. These biomarkers were subsequently prioritized with a convergent functional genomics approach using previous evidence in the field implicating them in AD. The best overall evidence was for a series of new, as well as some previously known genes, which are now newly shown to have functional evidence in humans as blood biomarkers: RAB7A, NPC2, TGFB1, GAP43, ARSB, PER1, GUSB, and MAPT. Addnl. top blood biomarkers include GSK3B, PTGS2, APOE, BACE1, PSEN1, and TREM2, well known genes implicated in AD by previous brain and genetic studies, in humans and animal models, which serve as reassuring de facto pos. controls for our whole-genome gene expression discovery approach. A majority of top biomarkers also have evidence for involvement in other psychiatric disorders, particularly stress, providing a mol. basis for clin. co-morbidity and for stress as an early precipitant/risk factor. Some of them are modulated by existing drugs, such as antidepressants, lithium and omega-3 fatty acids. Other drug and nutraceutical leads were identified through bioinformatic drug repurposing analyses (such as pioglitazone, levonorgestrel, salsolidine, ginkgolide A, and icariin).

Molecular Psychiatry published new progress about Alzheimer disease. 163769-88-8 belongs to class quinoxaline, and the molecular formula is C22H21N3O2, COA of Formula: C22H21N3O2.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider